VoxNeuro is a Software as a Medical Device (SaMD) brain health company that analyzes brain-based biomarkers to assess cognitive function. We are pushing the boundaries of brain health and empowering physicians with a brain performance software. The Company delivers a comprehensive understanding of how a brain is functioning by measuring attention and concentration, information processing, and memory through its proprietary software.

Jason is an active member of the Board of Directors for Aequus Pharmaceuticals (TSX-V: AQS).

Think Research is an industry leader in delivering integrated digital healthcare solutions. The Company's focused mission is to organize the world's health knowledge so everyone gets the best care. Its evidence-based healthcare technology solutions support the clinical decision- making process, standardize care, and improve patient outcomes.

MDBriefCase specializes in developing innovative digital medical education. It partners with world-class pharmaceutical, medical device and biotech organizations while ensuring its innovative CME programs reflect the local experiences of healthcare professionals around the world. MDBC’s CME programs are available to almost 300,000 HCPs that rely on the company for high-quality, digital and accredited medical education.

Telo Genomics (formerly 3D Signatures) is a personalized medicine company with a proprietary software platform based on the three-dimensional analysis of telomere organization. The technology is supported by 25+ clinical studies on over 3,000 patients across 20 different cancers and Alzheimer’s disease. Depending on the application, the technology can measure the stage of disease, rate of progression of disease, drug efficacy, and drug toxicity. The technology is designed to predict the course of disease and to personalize treatment for the individual patient. For more information, visit the Company’s new website at www.3dsignatures.com.

Pro Bono Bio is an international healthcare company, based in the UK, which aims to provide safe, effective and quality healthcare while reducing the impact of drugs. Through the use of proprietary platform technologies and medical devices, PBB strives to reduce the level of drug burden for the patient while reducing costs to payors and society. PBB is working with partners around the world to establish distribution agreements in all major markets outside of the UK.

Jason was a member of executive leadership team member with responsibility for developing the business strategy and commercial plans to deliver early growth for Knight Therapeutics Inc. (TSX : GUD) and its shareholders. Knight Therapeutics (www.gud-knight.com) is a publicly-traded, specialty pharmaceutical company focused on acquiring, in-licensing, selling and marketing innovative prescription and over-the-counter pharmaceutical products. Knight conducts late-stage clinical development on low risk, low expense product opportunities. All of Knight’s products are sourced through partnerships.

The founders of Orphan Canada, Jason Flowerday and Joost van der Mark, combined 40 years of pharmaceutical industry and entrepreneurial experience to successfully in-license various specialty medicines and build a company with a wide-array of partnerships. These accomplishments and the desire to further commercialize its lead products, led to Orphan Canada selling its core assets to Knight Therapeutics (TSX : GUD) along with Jason and Joost joining Knight's leadership team.Orphan Canada is a specialty pharmaceutical company that was formed to commercialize therapies for genetic and rare diseases within the Canadian marketplace. Orphan Canada provided research-based companies and licensors with a commercial partner that was uniquely positioned to deliver maximum value to all stakeholders.

After a very successful six years of company leadership, Jason Flowerday made the decision to sell RxMedia Healthcare Communications. Jason worked closely to build a talented team and successful company along with his business partner Rory Tekanoff.From 2006 to 2012, Jason owned and led the company through a period of sustained growth and expansion. During a period of unprecedented industry contraction, RxMedia increased revenues ten-fold and achieved year-over-year growth in profits through building out the organization’s breadth of innovative products and services with clients in Canada, the U.S.A. and Europe. Through the dedication and continuous improvement of its employees, along with a wide-array of educational strategies, RxMedia excelled at forming lasting partnerships with a number of class-leading pharmaceutical companies.